Published in FASEB J on September 01, 1993
Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med (2007) 3.18
Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J Biol Chem (2009) 0.92
Membrane receptors and transporters involved in the function and transport of vitamin A and its derivatives. Biochim Biophys Acta (2011) 0.84
Differential and isomer-specific modulation of vitamin A transport and the catalytic activities of the RBP receptor by retinoids. J Membr Biol (2013) 0.78
Vitamin A Transport Mechanism of the Multitransmembrane Cell-Surface Receptor STRA6. Membranes (Basel) (2015) 0.77
Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients. Br J Cancer (1997) 0.75
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 3.30
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast. Genes Dev (2000) 2.82
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst (1999) 2.81
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst (2000) 2.06
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
Early T-helper cell defects in HIV infection. AIDS (1991) 1.93
Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol (1996) 1.93
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS (1999) 1.89
Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis (1999) 1.88
Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS (1998) 1.86
Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84
Hawking radiation from ultrashort laser pulse filaments. Phys Rev Lett (2010) 1.80
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest (1989) 1.77
Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today (1996) 1.75
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol (2000) 1.69
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.69
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS (2000) 1.66
Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65
Alloimmunization as an AIDS vaccine? Science (1993) 1.58
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Characterization of mec1 kinase-deficient mutants and of new hypomorphic mec1 alleles impairing subsets of the DNA damage response pathway. Mol Cell Biol (2001) 1.53
Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. Lancet (1998) 1.50
Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest (1991) 1.44
Effect of imatinib on haematopoietic recovery following idarubicin exposure. Leukemia (2003) 1.43
In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis (1996) 1.41
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr (1999) 1.41
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res (1996) 1.39
Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS (1996) 1.39
A strategy for prophylactic vaccination against HIV. Science (1993) 1.38
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis (1996) 1.36
CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol (1996) 1.35
N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res (1993) 1.33
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett (2001) 1.31
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol (2011) 1.30
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol (1993) 1.25
T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS (2001) 1.23
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS (2001) 1.16
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori (1982) 1.16
Structure of pig plasma retinol-binding protein at 1.65 A resolution. Acta Crystallogr D Biol Crystallogr (1998) 1.12
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol (1995) 1.11
Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res (1993) 1.10
PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiol Aging (2005) 1.09
Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis (2000) 1.09
The PD-1/PD-L1 pathway in human pathology. Curr Mol Med (2012) 1.08
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS (2000) 1.07
IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene (2010) 1.05
Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol (1994) 1.05
Unusual malignant tumours in 49 patients with HIV infection. AIDS (1989) 1.04
Genetic correlates of protection against HIV infection: the ally within. J Intern Med (2009) 1.04
Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis (1991) 1.04
Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect (2000) 1.04
Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol (2001) 1.04
Human in vitro allogeneic responses. Demonstration of three pathways of T helper cell activation. J Immunol (1990) 1.03
In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett (1992) 1.03
Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J Pediatr (1995) 1.03
T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J Immunol (1993) 1.02
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol (2011) 1.00
Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. J Immunol (1995) 1.00
Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ (1995) 0.99
Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS (1996) 0.99
Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst (1998) 0.98
BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol (2009) 0.98
HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents (2000) 0.97
Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission. Clin Exp Immunol (2001) 0.96
Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer (2001) 0.96
T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. Chem Immunol (1992) 0.96
Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer (1996) 0.96
Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut (2007) 0.95
Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer (1991) 0.95
Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol (2009) 0.95
Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. Br J Cancer (1986) 0.95
Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplantation (1991) 0.95
The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis (2013) 0.94
Long-term balancing selection maintains trans-specific polymorphisms in the human TRIM5 gene. Hum Genet (2010) 0.93
The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst (1996) 0.93
Expressed emotion and schizophrenia in Italy. A study of an urban population. Br J Psychiatry (1992) 0.93
Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun (2001) 0.93
Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer J (2012) 0.92
Cytokine profiles in HIV type 1 disease and protection. AIDS Res Hum Retroviruses (1998) 0.92
Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood (1995) 0.92
Helper T-cell responses in children infected with human immunodeficiency virus type 1. J Pediatr (1991) 0.92